Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: SH2B3

Gene summary for SH2B3

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

SH2B3

Gene ID

10019

Gene nameSH2B adaptor protein 3
Gene AliasIDDM20
Cytomap12q24.12
Gene Typeprotein-coding
GO ID

GO:0000165

UniProtAcc

B7Z7K6


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
10019SH2B3HCC1_MengHumanLiverHCC2.36e-103.63e-020.0246
10019SH2B3HCC2HumanLiverHCC2.53e-051.45e+000.5341
10019SH2B3Pt13.bHumanLiverHCC4.65e-072.04e-010.0251
10019SH2B3S027HumanLiverHCC6.28e-075.44e-010.2446
10019SH2B3S028HumanLiverHCC6.29e-125.15e-010.2503
10019SH2B3S029HumanLiverHCC1.37e-136.61e-010.2581
10019SH2B3C21HumanOral cavityOSCC3.86e-061.94e-010.2678
10019SH2B3C30HumanOral cavityOSCC5.85e-115.17e-010.3055
10019SH2B3C38HumanOral cavityOSCC3.33e-034.37e-010.172
10019SH2B3C43HumanOral cavityOSCC1.34e-039.16e-020.1704
10019SH2B3EOLP-1HumanOral cavityEOLP1.25e-215.08e-01-0.0202
10019SH2B3SYSMH5HumanOral cavityOSCC1.51e-036.66e-020.0647
Page: 1 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:003410912LiverHCChomotypic cell-cell adhesion55/795890/187232.81e-042.02e-0355
GO:00301952LiverHCCnegative regulation of blood coagulation33/795849/187233.86e-042.62e-0333
GO:00075992LiverHCChemostasis119/7958222/187235.25e-043.41e-03119
GO:19000472LiverHCCnegative regulation of hemostasis33/795850/187236.74e-044.15e-0333
GO:00434097LiverHCCnegative regulation of MAPK cascade98/7958180/187237.88e-044.74e-0398
GO:00508172LiverHCCcoagulation118/7958222/187238.41e-045.03e-03118
GO:005087822LiverHCCregulation of body fluid levels191/7958379/187231.06e-036.11e-03191
GO:00508192LiverHCCnegative regulation of coagulation34/795853/187231.20e-036.68e-0334
GO:007052712LiverHCCplatelet aggregation40/795867/187233.35e-031.53e-0240
GO:0071901LiverHCCnegative regulation of protein serine/threonine kinase activity66/7958120/187233.81e-031.68e-0266
GO:00341102LiverHCCregulation of homotypic cell-cell adhesion22/795833/187234.38e-031.90e-0222
GO:0034111LiverHCCnegative regulation of homotypic cell-cell adhesion11/795814/187236.81e-032.73e-0211
GO:0043407LiverHCCnegative regulation of MAP kinase activity34/795859/187231.36e-024.84e-0234
GO:005134820Oral cavityOSCCnegative regulation of transferase activity165/7305268/187235.02e-142.74e-12165
GO:004206020Oral cavityOSCCwound healing237/7305422/187234.51e-132.18e-11237
GO:001056320Oral cavityOSCCnegative regulation of phosphorus metabolic process246/7305442/187236.12e-132.89e-11246
GO:004593620Oral cavityOSCCnegative regulation of phosphate metabolic process245/7305441/187238.85e-134.09e-11245
GO:003009920Oral cavityOSCCmyeloid cell differentiation213/7305381/187231.24e-114.42e-10213
GO:004232619Oral cavityOSCCnegative regulation of phosphorylation214/7305385/187232.30e-117.74e-10214
GO:007190010Oral cavityOSCCregulation of protein serine/threonine kinase activity201/7305359/187233.90e-111.27e-09201
Page: 1 2 3 4 5 6 7 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa0472210LiverHCCNeurotrophin signaling pathway74/4020119/84658.27e-043.26e-031.81e-0374
hsa0472211LiverHCCNeurotrophin signaling pathway74/4020119/84658.27e-043.26e-031.81e-0374
hsa0472220Oral cavityOSCCNeurotrophin signaling pathway74/3704119/84653.55e-051.49e-047.58e-0574
hsa04722110Oral cavityOSCCNeurotrophin signaling pathway74/3704119/84653.55e-051.49e-047.58e-0574
hsa0472242Oral cavityEOLPNeurotrophin signaling pathway36/1218119/84656.23e-063.87e-052.28e-0536
hsa0472252Oral cavityEOLPNeurotrophin signaling pathway36/1218119/84656.23e-063.87e-052.28e-0536
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
SH2B3SNVMissense_Mutationrs765614074c.1099G>Ap.Gly367Serp.G367SQ9UQQ2protein_codingdeleterious(0)probably_damaging(1)TCGA-AN-A0AK-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
SH2B3SNVMissense_Mutationrs559278672c.1192N>Tp.Arg398Cysp.R398CQ9UQQ2protein_codingdeleterious(0)probably_damaging(0.997)TCGA-BH-A0DS-01Breastbreast invasive carcinomaFemale>=65III/IVChemotherapycyclophosphamideSD
SH2B3insertionIn_Frame_Insnovelc.780_781insTTTGGGCTGCCTCTGCTTTCCATCCCTp.Val260_Arg261insPheGlyLeuProLeuLeuSerIleProp.V260_R261insFGLPLLSIPQ9UQQ2protein_codingTCGA-A2-A0EX-01Breastbreast invasive carcinomaFemale<65I/IIHormone TherapytamoxiphenSD
SH2B3SNVMissense_Mutationnovelc.56N>Ap.Pro19Glnp.P19QQ9UQQ2protein_codingdeleterious(0.02)benign(0.012)TCGA-DS-A1OD-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinSD
SH2B3SNVMissense_Mutationrs374482426c.1393G>Ap.Val465Ilep.V465IQ9UQQ2protein_codingtolerated(0.84)benign(0.069)TCGA-AA-3947-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
SH2B3SNVMissense_Mutationc.1693C>Ap.Leu565Metp.L565MQ9UQQ2protein_codingtolerated(0.17)benign(0.155)TCGA-AA-A02R-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownPD
SH2B3SNVMissense_Mutationc.1507N>Ap.Ser503Thrp.S503TQ9UQQ2protein_codingtolerated(0.47)benign(0.005)TCGA-AY-6196-01Colorectumcolon adenocarcinomaMale<65III/IVUnknownUnknownSD
SH2B3SNVMissense_Mutationnovelc.1231G>Ap.Ala411Thrp.A411TQ9UQQ2protein_codingdeleterious(0)probably_damaging(0.996)TCGA-F4-6856-01Colorectumcolon adenocarcinomaMale<65I/IIAncillaryleucovorinCR
SH2B3SNVMissense_Mutationc.674N>Ap.Arg225Hisp.R225HQ9UQQ2protein_codingdeleterious(0)probably_damaging(0.983)TCGA-WS-AB45-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
SH2B3SNVMissense_Mutationnovelc.1175N>Ap.Arg392Glnp.R392QQ9UQQ2protein_codingdeleterious(0)probably_damaging(1)TCGA-A5-A0G1-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
Page: 1 2 3 4 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
10019SH2B3CLINICALLY ACTIONABLE, KINASEcandesartanCANDESARTAN31327267
Page: 1